{"id":"W1513839038","doi":"10.1056/nejmoa1502000","title":"Idarucizumab for Dabigatran Reversal","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1454,"is_retracted":false,"has_abstract":true,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"","keywords":"Idarucizumab; Medicine; Dabigatran; Hemostasis; Anesthesia; Anticoagulant; Surgery; Warfarin; Internal medicine; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1526281816432923,"score_gpt":0.3796013174481788,"score_spread":0.2269731358048864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}